PP
CDTX

Pacifica Partners’s Cidara Therapeutics CDTX Stock Holding History

Pacifica Partners’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-400
Closed -$4.3K – 486
2024
Q3 		$4.3K Hold
400
– – ﹤0.01% 410
2024
Q2 		$4.8K Hold
400
– – ﹤0.01% 408
2024
Q1 		$5.95K Hold
400
– – ﹤0.01% 397
2023
Q4 		$6.16K Hold
400
– – ﹤0.01% 413
2023
Q3 		$7.78K Hold
400
– – ﹤0.01% 378
2023
Q2 		$8.96K Hold
400
– – 0.01% 312
2023
Q1 		$9.48K Hold
400
– – 0.01% 321
2022
Q4 		$5.28K Hold
400
– – ﹤0.01% 345
2022
Q3 		$5K Hold
400
– – ﹤0.01% 364
2022
Q2 		$4K Hold
400
– – ﹤0.01% 384
2022
Q1 		$6K Hold
400
– – ﹤0.01% 351
2021
Q4 		$9K Hold
400
– – 0.01% 311
2021
Q3 		$18K Hold
400
– – 0.01% 233
2021
Q2 		$16K Hold
400
– – 0.01% 229
2021
Q1 		$21K Buy
+400
New +$19.8K 0.02% 196

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Pacifica Partners's CDTX Position: Q4 2024 in Review

Pacifica Partners sold out of Cidara Therapeutics (CDTX) in Q4 2024, closing a stake of 400 shares — an estimated $4.3K sold.

Pacifica Partners first reported a position in CDTX in Q1 2021 and held it in 15 quarters. The position peaked at $21K in Q1 2021. 40 funds tracked by Wall St. Rank hold CDTX as of Q4 2024.

  • Pacifica Partners reported no remaining Cidara Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Pacifica Partners sold 400 Cidara Therapeutics shares in Q4 2024, an estimated $4.3K.
  • Pacifica Partners first reported a position in Cidara Therapeutics in Q1 2021 and held it in 15 quarters.
  • Pacifica Partners's Cidara Therapeutics position peaked at $21K in Q1 2021.
  • 40 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2024.

Based on Pacifica Partners's 13F filing for Q4 2024, filed 14 Jan 2025.